Kernel, founded in 2016 by Bryan Johnson, is a neurotechnology company based in Los Angeles, California. The company's core mission is to advance brain-machine interfaces to transform neuromedicine. Kernel's innovative neuroimaging platform aims to accelerate treatment development, improve patient outcomes, and reduce healthcare costs by leveraging brain-based biomarkers to predict treatment responses. This technology empowers clinicians with more data for decision-making, leading to better patient care.
Notable affiliated individuals include Bryan Johnson, the founder, who initially invested $54 million into the company. Kernel has made significant strides in the neurotech field, contributing to the development of non-invasive brain-machine interfaces that have the potential to revolutionize medical treatments and diagnostics. By making neuroimaging more precise, reliable, and accessible, Kernel is poised to have a lasting impact on healthcare and patient outcomes globally.
